ResMed (RMD)
(Delayed Data from NYSE)
$218.57 USD
-1.40 (-0.64%)
Updated May 17, 2024 04:00 PM ET
After-Market: $218.56 -0.01 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RMD 218.57 -1.40(-0.64%)
Will RMD be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RMD
Haemonetics' (HAE) Hospital & Plasma Segments, Innovation Aid
Maravai (MRVI) Advances in RNA Research With New Collaboration
RMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Haemonetics (HAE) Stock Up 10.9% YTD: Will the Rally Continue?
What Makes ResMed (RMD) a New Strong Buy Stock
Align Technology (ALGN) Gains From Innovation, Global Expansion
Other News for RMD
$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today
Here are the biggest single-session post-results gains from the recent earnings season
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
MatrixCare Joins Health Gorilla’s Qualified Health Information Network (QHIN) to Enhance Patient Data Access
ResMed's MatrixCar partners with Health Gorilla